Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05751187 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Mar 30, 2026 to Dec 15, 2025
    • Study completion date: Mar 30, 2027 to Dec 30, 2027
    • Site details revised
    v4
  2. Start date changed from estimate of Jun 30, 2023 to Jun 27, 2023v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 30, 2023 to Jun 30, 2023
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.
Trial Details
NCT Number NCT05751187
Lead Sponsor Shanghai Chest Hospital
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Non-squamous NSCLC
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov